HRP20190936T1 - Amorfni letermovir i njegove krute farmaceutske formulacije za oralnu primjenu - Google Patents
Amorfni letermovir i njegove krute farmaceutske formulacije za oralnu primjenu Download PDFInfo
- Publication number
- HRP20190936T1 HRP20190936T1 HRP20190936TT HRP20190936T HRP20190936T1 HR P20190936 T1 HRP20190936 T1 HR P20190936T1 HR P20190936T T HRP20190936T T HR P20190936TT HR P20190936 T HRP20190936 T HR P20190936T HR P20190936 T1 HRP20190936 T1 HR P20190936T1
- Authority
- HR
- Croatia
- Prior art keywords
- letermovir
- solid pharmaceutical
- pharmaceutical formulation
- hcmv
- amorphous state
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13003120 | 2013-06-19 | ||
| EP14165027 | 2014-04-16 | ||
| EP14732545.0A EP3010891B1 (en) | 2013-06-19 | 2014-06-19 | Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration |
| PCT/EP2014/062974 WO2014202737A1 (en) | 2013-06-19 | 2014-06-19 | Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190936T1 true HRP20190936T1 (hr) | 2019-10-04 |
Family
ID=50982905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190936TT HRP20190936T1 (hr) | 2013-06-19 | 2014-06-19 | Amorfni letermovir i njegove krute farmaceutske formulacije za oralnu primjenu |
Country Status (34)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10319612A1 (de) | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
| DE102012101673A1 (de) | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
| KR101953270B1 (ko) * | 2013-06-19 | 2019-02-28 | 아이쿠리스 안티-인펙티브 큐어스 게엠베하 | 무정형 레터모비어 및 그의 경구 투여용 고체 제약 제제 |
| CA3019508A1 (en) | 2016-03-31 | 2017-10-05 | Intercept Pharmaceuticals, Inc. | Oral preparation having exceptional elutability |
| US20220152028A1 (en) * | 2019-03-12 | 2022-05-19 | Microbiotix, Inc. | Combination drug treatment for human cytomegalovirus |
| CN111024861A (zh) * | 2019-12-31 | 2020-04-17 | 山东省药学科学院 | 一种莱特莫韦及含莱特莫韦的制剂中有关物质的检测方法 |
| EP3906929A1 (en) | 2020-05-08 | 2021-11-10 | AiCuris GmbH & Co. KG | Letermovir for use in the prevention and the treatment of coronavirus infections |
| WO2022038457A1 (en) | 2020-08-17 | 2022-02-24 | Lupin Limited | A precipitation process for amorphous letermovir |
| WO2022132676A1 (en) * | 2020-12-16 | 2022-06-23 | Merck Sharp & Dohme Corp. | Mini-tablet dosage form of a viral terminase inhibitor and uses thereof |
| CN115403528B (zh) * | 2021-05-27 | 2025-01-07 | 南京正大天晴制药有限公司 | 无定形3,4-二氢喹唑啉衍生物的制备方法 |
| CN114942278B (zh) * | 2022-04-12 | 2023-09-08 | 山东诚创蓝海医药科技有限公司 | 来特莫韦中间体二d-(+)-二对甲基苯甲酰酒石酸乙酸乙酯络合物有关物质的分析方法 |
| WO2024037485A1 (zh) * | 2022-08-15 | 2024-02-22 | 上海迪赛诺化学制药有限公司 | 一种来特莫韦无定形的制备方法 |
| CN116338119A (zh) * | 2023-02-24 | 2023-06-27 | 重庆希韦医药科技有限公司 | 一种来特莫韦包合物溶液体外释放度的测定方法 |
| TW202535393A (zh) | 2023-12-21 | 2025-09-16 | 德商Ａｉｃ246股份兩合公司 | 2-[(4r,s)-8-氟-2-[4-(3-甲氧基苯基)哌嗪-1-基]-3-[2-甲氧基-5-(三氟甲基)苯基]-3,4-二氫喹唑啉-4-基]乙酸之非鏡像異構物胺基醇鹽及胺基醚鹽及其於鏡像異構物分離之用途 |
| WO2025216283A1 (ja) * | 2024-04-12 | 2025-10-16 | 東和薬品株式会社 | レテルモビル含有医薬組成物ならびにその製造方法および用途 |
| CN119745803A (zh) * | 2024-12-30 | 2025-04-04 | 上海奥科达医药科技股份有限公司 | 一种来特莫韦制剂组合物及其制备方法 |
| CN120927867A (zh) * | 2025-10-11 | 2025-11-11 | 成都诺和晟欣生物医药有限公司 | 一种来特莫韦注射液中对映异构体的hplc检测方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10207026A1 (de) * | 2002-02-20 | 2003-08-28 | Boehringer Ingelheim Kg | Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung |
| DE10319612A1 (de) * | 2003-05-02 | 2004-11-18 | Bayer Healthcare Ag | Substituierte Dihydrochinazoline |
| DE10305785A1 (de) * | 2003-02-12 | 2004-08-26 | Bayer Healthcare Ag | Dihydrochinazoline |
| DE10338402A1 (de) * | 2003-08-18 | 2005-03-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum |
| CN101198314A (zh) * | 2005-04-12 | 2008-06-11 | 伊兰制药国际有限公司 | 纳米微粒喹唑啉衍生物制剂 |
| DE102005027517A1 (de) * | 2005-06-15 | 2006-12-21 | Bayer Healthcare Ag | Verfahren zur Herstellung von Dihydrochinazolinen |
| WO2012151271A1 (en) * | 2011-05-04 | 2012-11-08 | Merck Sharp & Dohme Corp. | Processes for preparing inhibitors of the hepatitis c virus |
| DE102012101673A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
| DE102012101680A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat |
| DE102012101659A1 (de) * | 2012-02-29 | 2013-08-29 | Aicuris Gmbh & Co. Kg | Salze eines Dihydrochinazolinderivats |
| WO2014047562A2 (en) * | 2012-09-21 | 2014-03-27 | Epiphany Biosciences | Method of treating and/or preventing shingles and method of treating and/or preventing zoster associated pain |
| KR101953270B1 (ko) * | 2013-06-19 | 2019-02-28 | 아이쿠리스 안티-인펙티브 큐어스 게엠베하 | 무정형 레터모비어 및 그의 경구 투여용 고체 제약 제제 |
-
2014
- 2014-06-19 KR KR1020167001010A patent/KR101953270B1/ko active Active
- 2014-06-19 MD MDA20150126A patent/MD4673C1/ro active IP Right Grant
- 2014-06-19 PL PL14732545T patent/PL3010891T3/pl unknown
- 2014-06-19 US US14/899,178 patent/US10442773B2/en active Active
- 2014-06-19 PE PE2015002639A patent/PE20160659A1/es unknown
- 2014-06-19 WO PCT/EP2014/062974 patent/WO2014202737A1/en not_active Ceased
- 2014-06-19 CA CA2916143A patent/CA2916143C/en active Active
- 2014-06-19 JP JP2016520499A patent/JP6445546B2/ja active Active
- 2014-06-19 UA UAA201600339A patent/UA117755C2/uk unknown
- 2014-06-19 HR HRP20190936TT patent/HRP20190936T1/hr unknown
- 2014-06-19 AU AU2014283231A patent/AU2014283231B2/en active Active
- 2014-06-19 SG SG11201510426PA patent/SG11201510426PA/en unknown
- 2014-06-19 SM SM20190327T patent/SMT201900327T1/it unknown
- 2014-06-19 ES ES14732545T patent/ES2730958T3/es active Active
- 2014-06-19 HU HUE14732545A patent/HUE043721T2/hu unknown
- 2014-06-19 NZ NZ715387A patent/NZ715387A/en unknown
- 2014-06-19 MX MX2015017758A patent/MX373764B/es active IP Right Grant
- 2014-06-19 CN CN201480040969.XA patent/CN105555771B/zh active Active
- 2014-06-19 EP EP14732545.0A patent/EP3010891B1/en active Active
- 2014-06-19 CN CN202510264255.7A patent/CN120097924A/zh active Pending
- 2014-06-19 CU CU2015000179A patent/CU24619B1/es unknown
- 2014-06-19 PT PT14732545T patent/PT3010891T/pt unknown
- 2014-06-19 RS RS20190686A patent/RS58882B1/sr unknown
- 2014-06-19 DK DK14732545.0T patent/DK3010891T3/da active
- 2014-06-19 ME MEP-2019-149A patent/ME03483B/me unknown
- 2014-06-19 EA EA201600024A patent/EA036131B1/ru unknown
- 2014-06-19 MY MYPI2015002983A patent/MY179502A/en unknown
- 2014-06-19 SI SI201431243T patent/SI3010891T1/sl unknown
- 2014-06-19 BR BR112015031979-3A patent/BR112015031979B1/pt active IP Right Grant
- 2014-06-19 LT LTEP14732545.0T patent/LT3010891T/lt unknown
-
2015
- 2015-12-18 DO DO2015000303A patent/DOP2015000303A/es unknown
- 2015-12-18 PH PH12015502821A patent/PH12015502821B1/en unknown
- 2015-12-18 ZA ZA2015/09239A patent/ZA201509239B/en unknown
- 2015-12-20 IL IL243228A patent/IL243228B/en active IP Right Grant
-
2018
- 2018-09-07 JP JP2018168220A patent/JP6770035B2/ja active Active
- 2018-12-26 IL IL263978A patent/IL263978B/en active IP Right Grant
-
2019
- 2019-06-11 CY CY20191100607T patent/CY1121732T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190936T1 (hr) | Amorfni letermovir i njegove krute farmaceutske formulacije za oralnu primjenu | |
| JP2018193401A5 (cg-RX-API-DMAC7.html) | ||
| TWI618547B (zh) | 緩釋藥物配方 | |
| JP2015531365A5 (cg-RX-API-DMAC7.html) | ||
| CA2787123C (en) | Rifaximin powder, process for preparing the same and controlled release compositions containing said rifaximin useful for obtaining a long-lasting effect | |
| IT9020054A1 (cg-RX-API-DMAC7.html) | ||
| WO2006070781A1 (ja) | 塩基性薬物又はその塩を含有するマトリックス型徐放性製剤およびその製造方法 | |
| CN108348475B (zh) | 处于液体剂型的多层药学活性化合物释放微粒 | |
| JP6576953B2 (ja) | リファキシミンの新規溶媒和物結晶形、生成物、組成物及びそれらの使用 | |
| PT2018159E (pt) | Formulação de libertação de fármacos no cólon | |
| ITMI20001603A1 (it) | Formulazioni farmaceutiche solide orali a rilascio multifasico ph-dipendente | |
| FI3283058T3 (fi) | Ribosiklibitabletti | |
| JPH07145052A (ja) | 良好な溶解特性を有する医薬組成物 | |
| JP2014501267A (ja) | メサラジン制御放出用の経口用医薬錠剤および前記錠剤を得るための製法 | |
| JP4540092B2 (ja) | 酸に不安定な生理活性化合物を含有する製剤組成物及びその製法 | |
| CN101287443A (zh) | pH控制的脉冲释放系统、其制备方法和用途 | |
| HRP20151051T1 (hr) | Formulacije src/abl inhibitora | |
| CN104146978A (zh) | 一种双硫仑肠溶片剂及其制备方法 | |
| CN103405395B (zh) | 匹可硫酸钠肠溶片及其制备方法 | |
| CN107106568B (zh) | 稠合氨基二氢噻嗪衍生物的药物组合物 | |
| WO2017026950A1 (en) | Controlled release propiverine formulations | |
| JP2006298811A (ja) | ゲル化抑制製剤の設計 | |
| JP2005060310A (ja) | 不快な味をマスキングする経口投与用製剤 | |
| US20060280788A1 (en) | Delivery and formulations of mast cell stabilizers | |
| Cruañes et al. | non-sink dissolution media for identification of functional formulation excipients—the case of a precipitation inhibitor |